Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Ugurel, S; Rebmann, V; Ferrone, S; Tilgen, W; Grosse-Wilde, H; Reinhold, U.
Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.
Cancer. 2001; 92(2):369-376
Doi: 10.1002/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Ugurel-Becker Selma
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND. The nonclassic human major histocompatibility complex class I antigens human leukocyte antigen (HLA)-G are proposed to protect tumor cells from natural killer cell lysis. In the current study, the authors measured soluble HLA-G molecules (sHLA-G) in serum from patients with malignant melanoma. METHODS, Soluble HLA-G was determined in serum samples of 190 melanoma patients with various stages of disease, with or without current therapy including interferon (IFN)-alpha and different cytostatics in comparison to 126 healthy controls by using a two-step enzyme-linked immunoadsorbent assay. RESULTS, Serum sHLA-G was significantly (P < 0.0005) elevated in melanoma patients (mean +/- standard error of the mean [SEM] = 41.95 +/- 2.15 ng/mL) compared with healthy controls (mean +/- SEM = 22.92 +/- 1.51 ng/mL). Univariate analysis revealed a correlation of sHLA-G serum level with advanced stages of disease (P < 0.001) and tumor load (P < 0.05). Patients undergoing immunotherapy with IFN-alpha (n = 31) showed an increased serum sHLA-G (mean +/- SEM = 62.05 +/- 7.58 ng/mL; P < 0.0005), whereas other treatment regimens (n = 24) did not influence sHLA-G serum concentrations. Multivariate analysis revealed treatment with IFN-alpha as the only impact factor for elevated serum sHLA-G, lacking any correlation with stage of disease or tumor burden. Furthermore, IFN-ru was found to upregulate HLA-G cell surface expression on circulating monocytes. sHLA-G serum level was not associated with recurrence free or overall survival. CONCLUSIONS, This study shows increased sHLA-G serum concentrations in melanoma patients and additional enhancement upon treatment with IFN-ol. The level of serum sHLA-G, however, had no negative impact on patients' prognosis. (C) 2001 Americnn Cancer Society.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal - diagnostic use
- Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use
- Biological Markers - analysis
- Enzyme-Linked Immunosorbent Assay -
- Female -
- Flow Cytometry -
- HLA Antigens - analysis HLA Antigens - biosynthesis
- Histocompatibility Antigens Class I - analysis Histocompatibility Antigens Class I - biosynthesis
- Humans -
- Interferon-alpha - pharmacology Interferon-alpha - therapeutic use
- Male -
- Melanoma - drug therapy Melanoma - immunology Melanoma - pathology
- Middle Aged -
- Prognosis -
- Prospective Studies -
- Skin Neoplasms - drug therapy Skin Neoplasms - immunology Skin Neoplasms - pathology
- Find related publications in this database (Keywords)
- medical oncology
- melanoma
- soluble human leukocyte antigen-G
- enzyme-linked immunoadsorbent assay (ELISA)
- interferon-alpha (IFN-alpha) therapy
- prognosis